Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Melanoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Rare Diseases 1Precancerous Conditions 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Muscle-invasive Bladder Cancer 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Hypertension, Portal 1Hepatitis C 1Fibrosis 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × tremelimumab × Clear all
NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Ludwig Institute for Cancer Research

Phase 1 Terminated
6 enrolled 11 charts
Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡